SCHEMBL980327

SCHEMBL980327

O=C1C(=Cc2ccccc2)CCc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 1.00
MIF P14174 9/20 0.81
MAPT P10636 4/20 0.81
CYP19A1 P11511 3/20 0.77
PKM P14618 2/20 0.77
CYP11B2 P19099 1/20 0.77
MAPK1 P28482 1/20 0.77
MAOA P21397 1/20 0.72
ALDH1A1 P00352 1/20 0.70
KMT2A Q03164 1/20 0.70
CYP1A2 P05177 1/20 0.69
CASP3 P42574 2/20 0.68
RAB9A P51151 2/20 0.68
SENP8 Q96LD8 2/20 0.68
SENP7 Q9BQF6 2/20 0.68
SENP6 Q9GZR1 2/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
KDM4E B2RXH2 1/20 0.65
NPC1 O15118 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15153677 1.00 MAOB (1.00) MAOBMIFMAPTCYP19A1PKM
SCHEMBL29546087 1.00 MAOB (1.00) MAOBMIFMAPTCYP19A1PKM
SCHEMBL29546151 1.00 MAOB (1.00) MAOBMIFMAPTCYP19A1PKM
SCHEMBL29679848 1.00 MAOB (1.00) MAOBMIFMAPTCYP19A1PKM
SCHEMBL820654 1.00 MAOB (1.00) MAOBMIFMAPTCYP19A1PKM
SCHEMBL6958006 0.90 MIF (1.00) MAOBMIFMAPTCYP19A1PKM
SCHEMBL13203410 0.90 MAOB (0.81) MAOBMIFMAPTCYP19A1PKM
SCHEMBL14033869 0.90 MAOB (0.81) MAOBMIFMAPTCYP19A1PKM
SCHEMBL8548101 0.87 MAOB (0.77) MAOBMIFMAPTCYP19A1PKM
SCHEMBL6825622 0.87 CYP19A1 (1.00) MAOBMIFMAPTCYP19A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104211642-B The synthesis and the application in cancer therapy drug of pyrazoline sulphone amide derivative of one class containing tetrahydronaphthalene or chroman skeleton 南京大学 2017-10-20 CN claimed
CN-104211642-A Synthesis of dihydropyrazol sulfanilamide derivatives containing tetrahydronaphthalene or chroman framework and application of derivatives in anti-cancer drugs NANJING UNIVERSITY OF TECHNOLOGY 2014-12-17 CN claimed
US-7166274-B2 Synergistically high SPF photoprotective UV-screening compositions comprising insoluble organic sunscreen particles/diarylbutadiene compounds L'OREAL (FR) 2007-01-23 US claimed
US-20040047820-A1 Synergistically high SPF photoprotective UV-screening compositions comprising insoluble organic sunscreen particles/diarylbutadiene compounds SOCIETE L'OREAL S.A. (FR) 2004-03-11 US claimed
US-6627180-B2 Particles having protection factor UV-APPD and an amino substituted 2-hydroxybenzophenone SOCIETE L'OREAL S.A. (FR) 2003-09-30 US claimed
US-20030152532-A1 SYNERGISTICALLY UV-PHOTOPROTECTING COMPOSITIONS COMPRISING MIXED SCREENING AGENTS SOCIETE L'OREAL S.A. (FR) 2003-08-14 US claimed
CN-115925530-B 3, 4-dihydronaphthalene-1 (2H) -one compound, preparation method and application 滨州医学院 2024-03-12 CN disclosed
US-11661407-B2 Process for the preparation of pyrylium salts COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2023-05-30 US disclosed
CN-115925530-A 3,4-dihydronaphthalene-1 (2H) -ketone compound, preparation method and application 滨州医学院 2023-04-07 CN disclosed
CN-112694449-B Asymmetric hydrogenation of ketone and alpha, beta-unsaturated ketone catalyzed by nonmetal catalyst 中国科学院化学研究所 2022-05-24 CN disclosed
US-11312694-B2 Method for making propenamide compound KING ABDULAZIZ UNIVERSITY (SA) 2022-04-26 US disclosed
EP-3561876-B1 DISPLAY NOVALED GMBH (DE) 2022-02-16 EP disclosed
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND KING ABDULAZIZ UNIVERSITY (SA) 2022-02-03 US disclosed
US-6627180-B2 Particles having protection factor UV-APPD and an amino substituted 2-hydroxybenzophenone SOCIETE L'OREAL S.A. (FR) 2003-09-30 US disclosed
US-20030152532-A1 SYNERGISTICALLY UV-PHOTOPROTECTING COMPOSITIONS COMPRISING MIXED SCREENING AGENTS SOCIETE L'OREAL S.A. (FR) 2003-08-14 US disclosed
US-20030027830-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2003-02-06 US disclosed
US-6462075-B1 USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2002-10-08 US disclosed
US-20020040029-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN, J. PHILLIP 2002-04-04 US disclosed
EP-0015156-A1 Basically-substituted tricyclic pyrazoles, their preparation and their use as antiinflammatory agents E.R. Squibb & Sons, Inc. (US) 1980-09-03 EP disclosed
US-4173634-A Basically-substituted tricyclic pyrazoles useful as antiinflammatory agents E. R. SQUIBB & SONS, INC. (US) 1979-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040029-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA MAOB 2579/4885MIF 534/4885MAPT 1111/4885
US-20030027830-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 MAOB 1509/4885MIF 220/4885MAPT 341/4885
US-20040047820-A1 Synergistically high SPF photoprotective UV-screening compositions comprising insoluble organic sunscreen particles/diarylbutadiene compounds SUCLG1, CUTA, DLD MAOB 1776/4885MIF 3072/4885MAPT 2067/4885
US-11312694-B2 Method for making propenamide compound APC, CYP2C19, PKD1 MAOB 790/4885MIF 4397/4885MAPT 3739/4885
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND APC, CYP2C19, PKD1 MAOB 790/4885MIF 4397/4885MAPT 3739/4885
US-11661407-B2 Process for the preparation of pyrylium salts SF3B5, IPO5, CYP4F11 MAOB 2613/4885MIF 1345/4885MAPT 2455/4885
US-20030152532-A1 SYNERGISTICALLY UV-PHOTOPROTECTING COMPOSITIONS COMPRISING MIXED SCREENING AGENTS HADHB, SDHA, ERCC4 MAOB 1274/4885MIF 2357/4885MAPT 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.